Overview
Progressive subcortical gliosis is a pathological condition characterized by the progressive proliferation of glial cells within the subcortical white matter of the brain, often associated with chronic neurological disorders and neurodegenerative processes. 1Diagnosis
Corneal injury model demonstrates simultaneous induction of corneal neovascularization and retinal gliosis, suggesting potential biomarkers for gliosis assessment. 1
Immunohistochemistry and western blotting are recommended for evaluating gliosis in affected tissues. 1Management
No specific pharmacological treatments for progressive subcortical gliosis are mentioned in the provided abstracts. 1
Withaferin A (WFA) showed efficacy in inhibiting processes related to angiogenesis and gliosis in an animal model, though direct application to human subcortical gliosis requires further investigation. 1Special Populations
No specific data on pregnancy, pediatrics, elderly, or comorbidities related to progressive subcortical gliosis are provided in the abstracts. 1Key Recommendations
Utilize animal models involving corneal injury and retinal analysis to assess potential therapeutic targets for gliosis inhibition. (Evidence: Expert opinion) 1
Consider withaferin A as a potential inhibitor for pathways related to gliosis based on preclinical efficacy, though clinical translation requires rigorous testing. (Evidence: Weak) 1
Further research is essential to establish diagnostic biomarkers and therapeutic interventions specific to progressive subcortical gliosis in humans. (Evidence: Expert opinion) 1References
1 Paranthan RR, Bargagna-Mohan P, Lau DL, Mohan R. A robust model for simultaneously inducing corneal neovascularization and retinal gliosis in the mouse eye. Molecular vision 2011. link